Welcure Drugs & Pharmaceuticals Ltd. has unveiled ambitious plans to establish an Agro-Pharma Research Laboratory, estimated to cost between ₹70-80 crore. The company also announced its intention to raise up to ₹80 crore through a Qualified Institutional Placement (QIP) to fund this initiative and for general corporate purposes.

Agro-Pharma Research Laboratory

The proposed laboratory will focus on converting agricultural and botanical inputs into pharma-grade products. Welcure Drugs aims to align the facility's design with current Good Manufacturing Practice (cGMP) standards and the U.S. Food and Drug Administration's (FDA) Botanical Drug Development guidance. This strategic move positions the company to potentially participate in broader international markets for botanical and ayurvedic products, subject to necessary approvals.

Market Opportunity

Welcure Drugs' initiative comes at a time of significant growth in the herbal and botanical medicine sector. According to industry sources cited in the company's disclosure:

These trends suggest a robust addressable market for compliant, evidence-based agro-derived therapeutics.

Funding Through QIP

To finance the Agro-Pharma Research Laboratory and for general corporate purposes, Welcure Drugs proposes to raise up to ₹80 crore through a Qualified Institutional Placement (QIP). The company plans to execute this fund-raise in one or more tranches, in accordance with SEBI regulations and other applicable laws.

Upcoming Board Meeting

A board meeting has been scheduled for August 28, 2025, to consider and potentially approve the QIP fund-raising proposal. The meeting will also address any necessary enabling resolutions, issue structure, and seek shareholders' approval as required.

Regulatory Compliance

Welcure Drugs has emphasized that the proposed project and fund-raise are subject to requisite board, shareholder, regulatory, and statutory approvals, as well as market conditions. The company has also confirmed that these proposals do not involve any related-party transactions.

In line with regulatory requirements, the trading window for the company's securities will remain closed until 48 hours after the announcement of the board meeting outcome.

As Welcure Drugs & Pharmaceuticals Ltd. embarks on this significant expansion into agro-pharma research, investors and industry observers will be keenly watching the developments that unfold following the upcoming board meeting.

Welcure Drugs & Pharmaceuticals Limited has announced a significant development that could potentially enhance its stock's accessibility and reward its shareholders. The company's Board of Directors is set to convene on August 22, 2025, to deliberate on two major corporate actions: a stock split and a bonus share issue.

Proposed Corporate Actions

Stock Split (Sub-division of Shares)

• Ratio: 1:10
• Proposal: One existing equity share to be split into ten equity shares
• Aim: To improve stock liquidity and affordability for investors

Bonus Share Issue

• Ratio: Up to 1:1
• Proposal: One bonus equity share for every one equity share held
• Subject to: Availability of adequate reserves

Key Points

• The proposals are subject to necessary approvals, including statutory and shareholder approvals.
• The company aims to enhance liquidity, broaden its shareholding base, and improve stock affordability for investors through these measures.
• The trading window for the company's securities will remain closed until 48 hours after the announcement of the Board meeting's outcome, in compliance with SEBI regulations.

Management Statement

Chintan Didawala Ganpat, Managing Director of Welcure Drugs & Pharmaceuticals, stated in the company's filing, "These proposals are being considered with the objective of enhancing liquidity, broad-basing shareholding and improving affordability for investors, subject to the Board's decision and subsequent statutory/shareholder approvals."

Next Steps

If approved by the Board:

• The company will announce the record date(s) for these corporate actions.
• Detailed terms, including the sequence and timetable of the corporate actions, will be intimated separately.
• All actions will be in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable laws.

Investors and stakeholders are advised to await the outcome of the Board meeting scheduled for August 22, 2025, for further details on these proposed corporate actions.

Note: The above proposals are subject to Board approval and all other applicable regulatory and statutory approvals.